Backed by a team of professional, we we manufacture, export and supply high quality Omarigliptin CAS 1226781-44-7. Omarigliptin CAS 1226781-44-7 is a panacea for some patient who suffer from Type 2 Diabetes. Omarigliptin CAS 1226781-44-7 is high purity, superior quality, fast action that are appreciated by many customers. Our aim is to offer more high quality product to customers from all the world. We own largest production base and professional staffs to ensure the inventory. We have ability to offer bulk needs for the customers.

Thera. Category:Antidiabetic

Cas No.: 1226781-44-7

Synonyms: MK-3102;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(Methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-aMine;MK-3012;(2S,3R,5S)-2-(2,5-Difluorophenyl)-5-[2-(Methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-aMine (MK-3102 enantioMer);(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine;OMarigliptin;OMarigliptin (MK-3102);2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine MK3102

Molecular Formula: C17H20F2N4O3S

Molecular Weight: 398.43

Assay: ≥99%

Packing: Export worthy packing

Material Safety Data Sheet: Available on request

Usage:

Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co.[1] It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP),[2][3][4] which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.